Biotech | April 29, 2022
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
Clears major obesity endpoints at 80 weeks
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
Subscribe To Our Newsletter & Stay Updated
